Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 2
1994 25
1995 38
1996 44
1997 65
1998 70
1999 85
2000 75
2001 114
2002 137
2003 128
2004 138
2005 147
2006 170
2007 167
2008 156
2009 152
2010 148
2011 133
2012 124
2013 127
2014 120
2015 89
2016 75
2017 64
2018 63
2019 54
2020 56
2021 46
2022 53
2023 37
2024 23

Search Results

2,555 results

Results by year

Filters applied: . Clear all
Page 1
MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study.
Mitchell JM, Bogenschutz M, Lilienstein A, Harrison C, Kleiman S, Parker-Guilbert K, Ot'alora G M, Garas W, Paleos C, Gorman I, Nicholas C, Mithoefer M, Carlin S, Poulter B, Mithoefer A, Quevedo S, Wells G, Klaire SS, van der Kolk B, Tzarfaty K, Amiaz R, Worthy R, Shannon S, Woolley JD, Marta C, Gelfand Y, Hapke E, Amar S, Wallach Y, Brown R, Hamilton S, Wang JB, Coker A, Matthews R, de Boer A, Yazar-Klosinski B, Emerson A, Doblin R. Mitchell JM, et al. Nat Med. 2021 Jun;27(6):1025-1033. doi: 10.1038/s41591-021-01336-3. Epub 2021 May 10. Nat Med. 2021. PMID: 33972795 Free PMC article. Clinical Trial.
MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial.
Mitchell JM, Ot'alora G M, van der Kolk B, Shannon S, Bogenschutz M, Gelfand Y, Paleos C, Nicholas CR, Quevedo S, Balliett B, Hamilton S, Mithoefer M, Kleiman S, Parker-Guilbert K, Tzarfaty K, Harrison C, de Boer A, Doblin R, Yazar-Klosinski B; MAPP2 Study Collaborator Group. Mitchell JM, et al. Nat Med. 2023 Oct;29(10):2473-2480. doi: 10.1038/s41591-023-02565-4. Epub 2023 Sep 14. Nat Med. 2023. PMID: 37709999 Free PMC article. Clinical Trial.
Equasy revisited.
Young AH. Young AH. J Psychopharmacol. 2021 May;35(5):499-500. doi: 10.1177/02698811211012604. Epub 2021 May 3. J Psychopharmacol. 2021. PMID: 33938311 No abstract available.
MDMA related neuro-inflammation and adenosine receptors.
Kermanian F, Seghatoleslam M, Mahakizadeh S. Kermanian F, et al. Neurochem Int. 2022 Feb;153:105275. doi: 10.1016/j.neuint.2021.105275. Epub 2022 Jan 3. Neurochem Int. 2022. PMID: 34990730 Review.
Oxytocin in response to MDMA provocation test in patients with arginine vasopressin deficiency (central diabetes insipidus): a single-centre, case-control study with nested, randomised, double-blind, placebo-controlled crossover trial.
Atila C, Holze F, Murugesu R, Rommers N, Hutter N, Varghese N, Sailer CO, Eckert A, Heinrichs M, Liechti ME, Christ-Crain M. Atila C, et al. Lancet Diabetes Endocrinol. 2023 Jul;11(7):454-464. doi: 10.1016/S2213-8587(23)00120-1. Epub 2023 May 13. Lancet Diabetes Endocrinol. 2023. PMID: 37192642 Clinical Trial.
2,555 results